title: Topical erythropoietin promotes wound repair in diabetic rats.
abstract: Wound healing in diabetic patients is slower than in healthy individuals. Erythropoietin (EPO) has non-hemopoietic targets in the skin, and systemically administered EPO promotes wound healing in experimental animals. This study investigated the effect of topical EPO treatment on defective wound repair in the skin of diabetic rats. Full-thickness excisional skin wounds were made in 38 rats, of which 30 had diabetes. The wounds were then treated topically with a cream that contained either vehicle, 600 IU ml(-1) EPO (low dose), or 3,000 IU ml(-1) (high dose) EPO. We assessed the rate of wound closure during the 12-day treatment period, and microvascular density (MVD), vascular endothelial growth factor (VEGF), and hydroxyproline (HP) contents, and the extent of apoptosis in wound tissues at the end of the 12-day treatment period. Topical EPO treatment significantly reduced the time to final wound closure. This increased rate of closure of the two EPO-treated wounds in diabetic rats was associated with increased MVD, VEGF, and HP contents, and a reduced extent of apoptosis. In light of our finding that topical EPO treatment promotes skin wound repair in diabetic rats, we propose that topical EPO treatment is a therapeutically beneficial method of treating chronic diabetic wounds.
authors.affiliation: The Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. saher@tx.technion.ac.il
authors.forename: Saher
authors.initials: S
authors.lastname: Hamed
authors.forename: Yehuda
authors.initials: Y
authors.lastname: Ullmann
authors.forename: Muhannad
authors.initials: M
authors.lastname: Masoud
authors.forename: Elias
authors.initials: E
authors.lastname: Hellou
authors.forename: Ziad
authors.initials: Z
authors.lastname: Khamaysi
authors.forename: Luc
authors.initials: L
authors.lastname: Teot
mesh_terms: D000287:Administration, Topical; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000150:complications*; D004921:Erythropoietin / Q000494:pharmacology*; D006909:Hydroxyproline / Q000378:metabolism; D008297:Male; D018919:Neovascularization, Physiologic / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D012867:Skin / Q000098:blood supply / Q000293:injuries* / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism; D014945:Wound Healing / Q000187:drug effects*; D014947:Wounds and Injuries / Q000150:complications* / Q000188:drug therapy*
chemical_list: D042461:Vascular Endothelial Growth Factor A; C467498:vascular endothelial growth factor A, rat; D004921:Erythropoietin; D006909:Hydroxyproline